PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.48) by 93.75 percent. This is a 100.3 percent decrease over earnings of $10.04 per share from the same period last year. The company reported quarterly sales of $272.551 million which beat the analyst consensus estimate of $218.805 million by 24.56 percent. This is a 76.82 percent decrease over sales of $1.176 billion the same period last year.